Physician profile

Michael Shapiro

Carson City, NV

NPI 1033200951

$27,149.37

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$26,907.50
Food and Beverage$174.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Scilex Pharmaceuticals INC. $26,907.50 2023-2024
Organogenesis INC. $103.99 2023-2024 Puraply
Pacira Pharmaceuticals Incorporated $54.27 2023 Iovera
Horizon Therapeutics Plc $28.53 2019-2020
Tersera Therapeutics LLC $26.74 2019
Depuy Synthes Sales INC. $16.08 2024 Monovisc, Orthovisc
Nevro Corp. $12.26 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Shapiro

$27,149.37

in general payments reported 2019-2025

Years
2019-2024
Top company
Scilex Pharmaceuticals INC.

https://glasscript.com/doctor/92425/michael-shapiro

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.